GlaxoSmithKline has offloaded the global rights to failed cardiovascular disease drug losmapimod to Fulcrum Therapeutics. Fulcrum plans to reposition the p38 mitogen-activated protein kinase inhibitor ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Shares of Cambridge-based ...
The company will complete a full evaluation of the data it received this week and plans to share the results at an upcoming medical meeting. In light of these results, the company plans to suspend the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results